Ofatumumab
Arzerra (ofatumumab) is a monoclonal antibody medication used primarily to treat chronic lymphocytic leukemia (CLL), a type of blood and bone marrow cancer. It works by targeting and depleting CD20-positive B cells, which are abnormal immune cells that accumulate in CLL. This medication is typically reserved for patients who have not responded to other standard CLL treatments.
Arzerra is a monoclonal antibody that targets and destroys abnormal B cells in patients with chronic lymphocytic leukemia.
Key facts at a glance
- RxNorm
- 876301
- Generic
- Arzerra
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Arzerra is FDA-approved for the treatment of chronic lymphocytic leukemia (CLL), specifically for patients whose cancer has not responded to fludarabine and alemtuzumab therapy. It may also be used in combination with other chemotherapy agents for certain CLL patients.
Arzerra is a monoclonal antibody that specifically binds to the CD20 protein found on the surface of B cells. Once bound, it triggers the immune system to attack and destroy these abnormal B cells through mechanisms including complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, effectively reducing the number of cancer cells in the body.
Arzerra is administered as an intravenous infusion in a clinical setting. Common side effects may include infusion reactions, infections, and decreased blood cell counts. Patients should be monitored closely during and after infusions, and appropriate prophylactic medications may be given to reduce the risk of infusion reactions. Vaccination history should be reviewed before treatment, as live vaccines are typically contraindicated during therapy.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed September 2, 2026. · Read our editorial policy